COMPUTATIONAL SCREENING OF NOVEL SMALL MOLECULES TARGETING KEY PROTEINS IN TYPE 2 DIABETES MELLITUS
Keywords:
type 2 diabetes mellitus; virtual screening; molecular docking; DPP-4; PTP1B; PPAR-gamma; alpha-glucosidase; ADMET; molecular dynamics.Abstract
Type 2 diabetes mellitus (T2DM) is a multifactorial metabolic disorder driven by insulin resistance, impaired insulin secretion, excessive postprandial glucose exposure, and dysregulated lipid and energy metabolism. The molecular heterogeneity of the disease has encouraged the use of computational approaches capable of evaluating candidate ligands against several mechanistically complementary targets. This study presents an integrated in silico framework for prioritizing small molecules against dipeptidyl peptidase-4 (DPP-4), protein tyrosine phosphatase 1B (PTP1B), peroxisome proliferator-activated receptor gamma (PPAR-gamma), and alpha-glucosidase. The workflow combines ligand standardization, physicochemical and drug-likeness filters, multi-target molecular docking, consensus ranking, ADMET assessment, and molecular-dynamics-oriented validation. A set of twelve hypothetical triazole-containing small molecules was used as a transparent illustrative case study; molecular descriptors were calculated directly, whereas docking scores and molecular-dynamics trajectories were included only to demonstrate ranking logic and must not be interpreted as experimentally generated data. The comparative analysis shows how multi-target ranking can identify candidates that balance predicted affinity with oral-drug-like properties rather than maximizing a single docking score. Candidates C12, C09, and C07 emerged as the strongest illustrative priorities because they combined favorable multi-target scores with acceptable calculated physicochemical descriptors and no major illustrative ADMET alerts. Literature evidence supports the relevance of DPP-4, PTP1B, PPAR-gamma, and carbohydrate-hydrolyzing enzymes as complementary T2DM targets and emphasizes the value of docking, molecular dynamics, and early ADMET prediction in reducing low-quality hits. The proposed framework is suitable as a reproducible template for future experimentally validated antidiabetic virtual-screening projects, provided that genuine docking, simulation, biochemical, and cellular measurements replace the illustrative values presented here.
References
1. Gomes, A. F. T., de Medeiros, W. F., Medeiros, I., Piuvezam, G., da Silva-Maia, J. K., Bezerra, I. W. L., & Morais, A. H. de A. (2024). In silico screening of therapeutic targets as a tool to optimize the development of drugs and nutraceuticals in the treatment of diabetes mellitus: A systematic review. International Journal of Molecular Sciences, 25(17), 9213. https://doi.org/10.3390/ijms25179213
2. Baranowska, J., Kiss, A., & Szeleszczuk, L. (2026). Molecular docking of natural compounds as DPP-4 inhibitors in type 2 diabetes: A comprehensive review. Pharmaceutics, 18(6), 741. https://doi.org/10.3390/pharmaceutics18060741
3. Shao, D.-W., Zhao, L.-J., & Sun, J.-F. (2024). Synthesis and clinical application of representative small-molecule dipeptidyl peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus (T2DM). European Journal of Medicinal Chemistry, 272, 116464. https://doi.org/10.1016/j.ejmech.2024.116464
4. Zhao, D., Sun, L., & Zhong, S. (2022). Discovery of inhibitors targeting protein tyrosine phosphatase 1B using a combined virtual screening approach. Molecular Diversity, 26(4), 2159-2174. https://doi.org/10.1007/s11030-021-10323-2
5. Debnath, A., Rani, A., Mazumder, R., Mazumder, A., Singh, R. K., Sharma, S., Srivastava, S., Chaudhary, H., Mishra, R., Khurana, N., Sanchitra, J., & Jan, S. A. (2026). Discovery of novel PTP1B inhibitors by high-throughput virtual screening. Current Computer-Aided Drug Design, 22(1), 61-86. https://doi.org/10.2174/0115734099278007241004105500
6. Lian, Y.-E., Wang, M., Ma, L., Yi, W., Liao, S., Gao, H., & Zhou, Z. (2024). Identification of novel PPARγ partial agonists based on virtual screening strategy: In silico and in vitro experimental validation. Molecules, 29(20), 4881. https://doi.org/10.3390/molecules29204881
7. Pan, G., Lu, Y., Wei, Z., Li, Y., Li, L., & Pan, X. (2024). A review on the in vitro and in vivo screening of α-glucosidase inhibitors. Heliyon, 10(18), e37467. https://doi.org/10.1016/j.heliyon.2024.e37467
8. Rashid, R. S. M., Temurlu, S., Abourajab, A., Karsili, P., Dinleyici, M., Al-Khateeb, B., & Icil, H. (2023). Drug repurposing of FDA compounds against α-glucosidase for the treatment of type 2 diabetes: Insights from molecular docking and molecular dynamics simulations. Pharmaceuticals, 16(4), 555. https://doi.org/10.3390/ph16040555
9. Huneif, M. A., Alshehri, D. B., Alshaibari, K. S., Dammaj, M. Z., Mahnashi, M. H., Majid, S. U., Javed, M. A., Ahmad, S., Rashid, U., & Sadiq, A. (2022). Design, synthesis and bioevaluation of new vanillin hybrid as multitarget inhibitor of α-glucosidase, α-amylase, PTP-1B and DPP4 for the treatment of type-II diabetes. Biomedicine & Pharmacotherapy, 150, 113038. https://doi.org/10.1016/j.biopha.2022.113038
10. Eberhardt, J., Santos-Martins, D., Tillack, A. F., & Forli, S. (2021). AutoDock Vina 1.2.0: New docking methods, expanded force field, and Python bindings. Journal of Chemical Information and Modeling, 61(8), 3891-3898. https://doi.org/10.1021/acs.jcim.1c00203
11. Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7, 42717. https://doi.org/10.1038/srep42717
12. Pires, D. E. V., Blundell, T. L., & Ascher, D. B. (2015). pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. Journal of Medicinal Chemistry, 58(9), 4066-4072. https://doi.org/10.1021/acs.jmedchem.5b00104
13. Abraham, M. J., Murtola, T., Schulz, R., Páll, S., Smith, J. C., Hess, B., & Lindahl, E. (2015). GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX, 1-2, 19-25. https://doi.org/10.1016/j.softx.2015.06.001
14. Zheng, Y., Ley, S. H., & Hu, F. B. (2018). Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nature Reviews Endocrinology, 14(2), 88-98. https://doi.org/10.1038/nrendo.2017.151
15. Kerru, N., Singh-Pillay, A., Awolade, P., & Singh, P. (2018). Current anti-diabetic agents and their molecular targets: A review. European Journal of Medicinal Chemistry, 152, 436-488. https://doi.org/10.1016/j.ejmech.2018.04.061
